Advertisement
Research Article

Role of Kras Status in Patients with Metastatic Colorectal Cancer Receiving First-Line Chemotherapy plus Bevacizumab: A TTD Group Cooperative Study

  • Eduardo Díaz-Rubio mail,

    ediazrubio.hcsc@salud.madrid.org

    Affiliation: Department of Medical Oncology, Hospital Clínico San Carlos (HCSC), Red Temática de Investigación Cooperativa en Cáncer (RD06/0020/0021), Facultad de Medicina, Universidad Complutense, Instituto de Investigación Sanitaria del HCSC (IdISSC), Madrid, Spain

    X
  • Auxiliadora Gómez-España,

    Affiliation: Department of Medical Oncology, Hospital Reina Sofía, Córdoba, Spain

    X
  • Bartomeu Massutí,

    Affiliation: Department of Medical Oncology, Hospital General, Alicante, Spain

    X
  • Javier Sastre,

    Affiliation: Department of Medical Oncology, Hospital Clínico San Carlos (HCSC), Red Temática de Investigación Cooperativa en Cáncer (RD06/0020/0021), Facultad de Medicina, Universidad Complutense, Instituto de Investigación Sanitaria del HCSC (IdISSC), Madrid, Spain

    X
  • Margarita Reboredo,

    Affiliation: Department of Medical Oncology, Complejo Hospitalario Universitario La Coruña, La Coruña, Spain

    X
  • José Luis Manzano,

    Affiliation: Department of Medical Oncology, Instituto Catalán de Oncología, Hospital Germans Trias I Pujol, Badalona, Spain

    X
  • Fernando Rivera,

    Affiliation: Department of Medical Oncology, Hospital Marqués de Valdecilla, Santander, Spain

    X
  • MªJosé Safont,

    Affiliation: Department of Medical Oncology, Hospital General de Valencia, Valencia, Spain

    X
  • Clara Montagut,

    Affiliation: Department of Medical Oncology, Hospital del Mar, Barcelona, Spain

    X
  • Encarnación González,

    Affiliation: Department of Medical Oncology, Hospital Virgen de las Nieves, Granada, Spain

    X
  • Manuel Benavides,

    Affiliation: Department of Medical Oncology, Hospital Universitario Carlos Haya, Málaga, Spain

    X
  • Eugenio Marcuello,

    Affiliation: Department of Medical Oncology, Hospital Santa Creu i Sant Pau, Barcelona, Spain

    X
  • Andrés Cervantes,

    Affiliation: Department of Medical Oncology, Institute of Health Research INCLIVA. University of Valencia, Valencia, Spain

    X
  • Purificación Martínez de Prado,

    Affiliation: Department of Medical Oncology, Hospital de Basurto, Vizcaya, Spain

    X
  • Carlos Fernández-Martos,

    Affiliation: Department of Medical Oncology, Instituto Valenciano de Oncología, Valencia, Spain

    X
  • Antonio Arrivi,

    Affiliation: Department of Medical Oncology, Fundación Hospital Son Llatzer, Palma de Mallorca, Spain

    X
  • Inmaculada Bando,

    Affiliation: Department of Medical Oncology, Hospital Clínico San Carlos (HCSC), Red Temática de Investigación Cooperativa en Cáncer (RD06/0020/0021), Facultad de Medicina, Universidad Complutense, Instituto de Investigación Sanitaria del HCSC (IdISSC), Madrid, Spain

    X
  • Enrique Aranda, on behalf of the Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD),

    Affiliation: Department of Medical Oncology, Hospital Reina Sofía, Córdoba, Spain

    X
  • E. Aranda

    Membership of the Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD) is provided in the Acknowledgments

    X
  • Published: October 12, 2012
  • DOI: 10.1371/journal.pone.0047345

About the Authors

Eduardo Díaz-Rubio, Javier Sastre, Inmaculada Bando
Department of Medical Oncology, Hospital Clínico San Carlos (HCSC), Red Temática de Investigación Cooperativa en Cáncer (RD06/0020/0021), Facultad de Medicina, Universidad Complutense, Instituto de Investigación Sanitaria del HCSC (IdISSC), Madrid, Spain
Auxiliadora Gómez-España, Enrique Aranda
Department of Medical Oncology, Hospital Reina Sofía, Córdoba, Spain
Bartomeu Massutí
Department of Medical Oncology, Hospital General, Alicante, Spain
Margarita Reboredo
Department of Medical Oncology, Complejo Hospitalario Universitario La Coruña, La Coruña, Spain
José Luis Manzano
Department of Medical Oncology, Instituto Catalán de Oncología, Hospital Germans Trias I Pujol, Badalona, Spain
Fernando Rivera
Department of Medical Oncology, Hospital Marqués de Valdecilla, Santander, Spain
MªJosé Safont
Department of Medical Oncology, Hospital General de Valencia, Valencia, Spain
Clara Montagut
Department of Medical Oncology, Hospital del Mar, Barcelona, Spain
Encarnación González
Department of Medical Oncology, Hospital Virgen de las Nieves, Granada, Spain
Manuel Benavides
Department of Medical Oncology, Hospital Universitario Carlos Haya, Málaga, Spain
Eugenio Marcuello
Department of Medical Oncology, Hospital Santa Creu i Sant Pau, Barcelona, Spain
Andrés Cervantes
Department of Medical Oncology, Institute of Health Research INCLIVA. University of Valencia, Valencia, Spain
Purificación Martínez de Prado
Department of Medical Oncology, Hospital de Basurto, Vizcaya, Spain
Carlos Fernández-Martos
Department of Medical Oncology, Instituto Valenciano de Oncología, Valencia, Spain
Antonio Arrivi
Department of Medical Oncology, Fundación Hospital Son Llatzer, Palma de Mallorca, Spain

Corresponding Author

Email: ediazrubio.hcsc@salud.madrid.org

Competing Interests

Eduardo Díaz-Rubio: Consultant or advisory role: Roche and Research Funding: Roche Enrique Aranda: Consultant or Advisory Role: Roche and Merck Serono Javier Sastre: Consultant or Advisory Role: Roche Andrés Cervantes. Consultant or Advisory Role: Roche and Merck Serono; Honoraria: Roche and Merck Serono; Research funding: Roche Fernando Rivera: Consultant or Advisory Role: Roche and Research Funding: Roche. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.

Author Contributions

Conceived and designed the experiments: EDR EA. Performed the experiments: EDR AGE BM JS MR JLM FR MJS CM EG MB EM AC PMP CFM AA IB EA. Analyzed the data: EDR EA. Contributed reagents/materials/analysis tools: EDR AGE BM JS MR JLM FR MJS CM EG MB EM AC PMP CFM AA IB EA. Wrote the paper: EDR EA.